Plain-English translation of NCT07223411 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is comparing two different immunotherapy combinations — Opdualag (which pairs two immune-boosting drugs) and a combination of fianlimab with cemiplimab — to see how well they work against advanced melanoma. The study will track how your immune system responds to whichever treatment you receive by examining immune cells in your blood and tumor tissue over time.
Melanoma is a serious form of skin cancer, and while newer immunotherapy treatments have improved survival rates, doctors want to understand exactly how these medications work at the cellular level so they can help patients better in the future.
You likely qualify if…
You likely don't qualify if…
You will be receiving one of the two immunotherapy treatments as part of the main study. For this additional research, you will have 3 extra tumor biopsies taken (small tissue samples) and 3 extra blood draws at scheduled visits. These samples help researchers understand how your immune system is responding to the treatment by analyzing specific immune cells.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Collaborators
Regeneron Pharmaceuticals
Enrollment target
~20 participants
Started
November 2025
Primary completion
November 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Danielle L Bednarz, RN
UPMC Hillman Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.